Compare QUIK & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUIK | SPRO |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.5M | 135.5M |
| IPO Year | 1997 | 2017 |
| Metric | QUIK | SPRO |
|---|---|---|
| Price | $10.80 | $2.78 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | 186.6K | ★ 328.8K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | N/A | ★ 0.15 |
| Revenue | $20,112,000.00 | ★ $66,802,000.00 |
| Revenue This Year | $75.17 | N/A |
| Revenue Next Year | $16.04 | $300.00 |
| P/E Ratio | ★ N/A | $18.07 |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $4.34 | $0.52 |
| 52 Week High | $10.37 | $3.09 |
| Indicator | QUIK | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 70.87 | 70.44 |
| Support Level | $5.96 | $2.15 |
| Resistance Level | N/A | $3.09 |
| Average True Range (ATR) | 0.60 | 0.14 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 97.98 | 99.14 |
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.